Search Results
118 results found-
Share buy-backs were undertaken at higher prices than the original subscription prices which reduced the historical balance for ordinary share contributed equity to nil.
https://www.csl.com/-/media/shared/documents/annual-report/csl-annual-report-2023.pdf -
e) participation in, acceptance of, or trading under, an offer or invitation made to all or most security holders such as a rights issue, a security purchase plan, CSL's Distribution Reinvestment Plan and an equal access buy back (
https://www.csl.com/-/media/shared/documents/one-csl/csl-governance-docs/securities-dealing-policy.pdf -
i. Share-based payments reserve Due to share buy-backs being undertaken at higher prices than The share-based payments reserve is used to recognise the the original subscription prices, the balance for ordinary share fair value of options, performance rights and GESP rights contributed equity has been reduced to nil, and a reserve created issued to employees.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2016-full.pdf -
CSL Seqirus is a global influenza vaccine provider developing innovative solutions.
https://www.csl.com/patients-public-health/vaccines -
GESP, including details of shares issued under the scheme, is set Due to share buy-backs being undertaken at higher prices than out in Note 5.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf -
Eblasakimab (Anti-IL-13R mAb) Atopic Dermatitis Mavrilimumab (Anti-GM-CSFR mAb) Giant Cell Arteritis, Rheumatoid Arthritis** *
https://www.csl.com/-/media/one-csl/sustainability/data-and-reporting-centre/documents/csl-limited-tax-transparency-report-2021-22.pdf -
Employees have the Can we proceed to buy from this supplier?
https://www.csl.com/-/media/shared/documents/one-csl/crbp-languages/csl_crbp2021_english_external.pdf -
To view the full ESWI program online, please visit:
https://newsroom.csl.com/2023-09-15-CSL-Seqirus-to-Present-at-9th-ESWI-Conference-on-the-Burden-of-Influenza-and-Impact-of-Vaccination-on-Public-Health -
Denteric is developing a therapeutic vaccine for the one billion people (one third of all adults) globally suffering from periodontal gum disease - a disease that is also associated with diabetes, heart disease, rheumatoid arthritis, dementia, and certain cancers.
https://newsroom.csl.com/2024-04-18-Jumar-Bioincubator-Release -
a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial," was published online on February 28, 2023.
https://newsroom.csl.com/2023-03-01-The-Lancet-Publishes-Pivotal-Phase-3-Data-on-CSLs-First-in-Class-Garadacimab-for-HAE